Isabelle Mahé: Bleeding Risk Differs Across Solid Tumours in Cancer-Associated Thrombosis
Isabelle Mahé, Head of Internal Medicine at the Louis Mourier Hospital, APHP at Paris Cité University, shared a post on LinkedIn about several recent articles she and her colleagues co-authored, adding:
“Another way to express that bleeding risk varies according to solid cancer site, with a low risk of CRB in breast cancer (6·2%) and a narrow range across other solid tumours (15·4–18·5%) (shown in figure 1 of the original Article recently published in The Lancet Haematology
Please read our reply just published in The Lancet Haematology!
In patients with CAT, reduced-dose apixaban is non inferior to full dose apixaban, and is associated with a significant 25% reduction in the risk of Clinically Relevant Bleeding (published in NEJM Group)”
Title 1: Predictors of clinically relevant bleeding during extended anticoagulation for cancer-associated venous thromboembolism (API-CAT): a post-hoc analysis of a randomised, non-inferiority trial
Authors: Isabelle Mahé, Céline Chapelle, Philippe Girard, Marc Carrier, Luis Jara Palomares, Charles-Marc Samama, Hélène Helfer, Grigoris Gerotziafas, Silvy Laporte, Eric Vicaut, Patrick Mismetti
Read the Full Article on The Lancet Haematology
Title 2: Predictors of clinically relevant bleeding during extended anticoagulation for cancer-associated VTE – Authors’ reply
Authors: Isabelle Mahé, Céline Chapelle, Silvy Laporte
Read the Full Article on The Lancet Haematology
Title 3: Extended Reduced-Dose Apixaban for Cancer-Associated Venous Thromboembolism
Authors: Isabelle Mahé, Marc Carrier, Didier Mayeur, Jean Chidiac, Eric Vicaut, Nicolas Falvo, Olivier Sanchez, Claire Grange, Manuel Monreal, Juan J. López-Núñez, Remedios Otero-Candelera, Grégoire Le Gal, Erik Yeo, Marc Righini, Helia Robert-Ebadi, Menno V. Huisman, Frederikus A. Klok, Peter Westerweel, Giancarlo Agnelli, Cecilia Becattini, Aristotelis Bamias, Kostas Syrigos, Sebastian Szmit, Adam Torbicki, Peter Verhamme, Anthony Maraveyas, Alexander T. Cohen, Cihan Ay, Céline Chapelle, Guy Meyer, Francis Couturaud, Patrick Mismetti, Philippe Girard, Laurent Bertoletti, Silvy Laporte
Read the Full Article on The New England Journal of Medicine
Faizan Khan, CIHR Banting Postdoctoral Fellow at University of Calgary, shared on LinkedIn about a recent article he and Nick van Es co-authored, adding:
”In a new publication from my Banting Canada postdoctoral fellowship out today in The Lancet Haematology, Nick van Es and I highlight the importance of considering different cancer sites for bleeding risk stratification in patients with cancer-associated Venous Thromboembolism.”
Title: Predictors of clinically relevant bleeding during extended anticoagulation for cancer-associated VTE
Authors: Faizan Khan, Nick van Es
Read the Full Article on The Lancet Haematology
Stay updated on all scientific advances with Hemostasis Today.
-
Apr 30, 2026, 18:19Deva Nanda TK: A Practical Overview of Dural Sinuses and The Venous Drainage of the Brain
-
Apr 30, 2026, 18:08Amrit Kaur Kaler: The Hidden Genetic Drivers of Thrombosis
-
Apr 30, 2026, 18:06Alejandro González Veliz: The Most Dangerous Mistake After Getting a Stent
-
Apr 30, 2026, 18:03Carmen Ruiz: First Arterial Mechanical Thrombectomy in New Zealand Using the ARTIX System
-
Apr 30, 2026, 17:52Simon Senanu: von Willebrand Disease May Be Missed Despite Normal Tests
-
Apr 30, 2026, 17:20José Antonio García Erce: Why Healthy Older Adults Should Keep Donating Blood?
-
Apr 30, 2026, 17:13Paul Logan: Decoding the Words ‘He’s on blood thinners’
-
Apr 30, 2026, 17:01Jason Andrade: A Decade-Long Quest Proves Early Ablation Halves Persistent AF Burden
-
Apr 30, 2026, 16:56Oliver Maracic: Could Co-Targeting ALK with FAK/PYK2 Help Mitigate the High VTE Burden Seen in ALK with NSCLC